Sansure Biotech's (SHA:688289) subsidiary, Zhongshan Sansure Haiji Biopharmaceutical, completed the domestic drug filing for the recombinant human growth hormone injection's workshop at China's National Medical Products Administration, according to a Shanghai Stock Exchange filing on Tuesday.
The Chinese molecular diagnostics and genetic testing products manufacturer will build a new production line in Zhongshan Torch High-Tech Industrial Development Zone, China, for the product after the approval.
The company's shares slipped more than 1% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。